THU0267 Ultrasonographic Salivary Glands Response to Rituximab in Primary SjöGren Syndrome Patients (Tears Sononographic Study)

Background Ultrasound (US) is a non-invasive tool validated to identify structural abnormalities of salivary glands and to diagnose primary Sjögren Syndrome patients (pSS) (1). However, no previous study evaluated the follow up and the potential improvement of treated pSS patients using ultrasonography. Objectives We conducted a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of Rituximab (RTX) in active pSS patients (TEARS study: Tolerance and EfficAcy of Rituximab in pSS)) and we evaluated in a single centre (Brest, France) the echostructural and vascularisation changes in this population. Methods The TEARS study included pSS patients with scores above 50 mmon at least two of four visual analog scales (VASs) evaluating dryness, pain, fatigue, and global disease. They were randomly assigned (1:1) to RTX (1 gat weeks 0 and 2) or placebo. Patient had recent-onset (